Association between admission anemia and long-term mortality in patients with acute myocardial infarction: results from the MONICA/KORA myocardial infarction registry

Miriam Giovanna Colombo¹²*, Inge Kirchberger¹²³, Ute Amann¹²³, Margit Heier¹², Christian Thilo⁴, Bernhard Kuch⁴⁵, Annette Peters² and Christa Meisinger¹²³

Abstract

Background: Previous studies have shown that the presence of anemia is associated with increased short- and long-term outcomes in patients with acute myocardial infarction (AMI). This study aims at examining the impact of admission anemia on long-term, all-cause mortality following AMI in patients recruited from a population-based registry. Contrary to most prior studies, we distinguished between patients with mild and moderate to severe anemia.

Methods: This prospective study was conducted in 2011 patients consecutively hospitalized for AMI that occurred between January 2005 and December 2008. Patients who survived more than 28 days after AMI were followed up until December 2011. Hemoglobin (Hb) concentration was measured at hospital admission and classified according to the World Health Organization (WHO). Mild anemia was defined as Hb concentration of 11 to < 12 g/dL in women and 11 to < 13 g/dL in men; moderate to severe anemia as Hb concentration of < 11 g/dL. Adjusted Cox regression models were calculated to compare survival in patients with and without anemia.

Results: Mild anemia and moderate to severe anemia was found in 183 (9.1%) and 100 (5%) patients, respectively. All-cause mortality after a median follow-up time of 4.2 years was 11.9%. The Cox regression analysis showed significantly increased mortality risks in both patients with mild (HR 1.74, 95% CI 1.23 – 2.45) and moderate to severe anemia (HR 2.05, 95% CI 1.37 – 3.05) compared to patients without anemia.

Conclusion: This study shows that anemia adversely affects long-term survival following AMI. However, further studies are needed to confirm that anemia can solely explain worse long-term outcomes after AMI.

Keywords: Myocardial infarction, Anemia, Hemoglobin, Mortality
neglecting severity of anemia. However, since it is a common condition found in hospitalized patients, severity of anemia might be important to consider [11]. In addition, results from long-term studies covering observation periods beyond 5 years are scarce. Therefore, the aim of this study was to examine the association between admission anemia and long-term, all-cause mortality in patients with AMI recruited from the MONICA/KORA myocardial infarction registry and to incorporate severity of anemia into the analysis.

Methods
The data for this study were derived from the Myocardial Infarction Registry that was established in Augsburg as part of the WHO project MONICA (Monitoring Trends and Determinants in Cardiovascular disease) in 1984. All coronary deaths and cases of non-fatal AMI occurring among the inhabitants of the city of Augsburg and the 2 adjacent counties (600,000 inhabitants) have been continuously registered since then. The population-based registry was included into the KORA (Cooperative Health Research in the Region of Augsburg) framework when the MONICA project ended in 1995.

Patients aged between 25 and 74 years, who were admitted to one out of 8 hospitals in the study area were included. Written informed consent had to be obtained before patients were included into the cohort. More detailed information on case identification, diagnostic classification of events and quality control of the data can be found in previous publications [12, 13]. Trained study nurses interviewed the participants during hospital stay using a standardized questionnaire. In order to confirm the information provided by the patients and to collect additional information, the patients’ medical chart was reviewed. Both methods of data collection and questionnaires have been approved by the ethics committee of the Bavarian Medical Association (Bayerische Landesärztekammer) and the study was performed in accordance with the Declaration of Helsinki.

We conducted this prospective study in consecutive patients hospitalized for AMI between January 1, 2005 and December 31, 2008. Patients were followed up for all-cause mortality, the outcome of this study, until December 31, 2011. The vital status of study participants after hospitalization periods beyond 5 years are scarce. Therefore, the aim of this study was to examine the association between admission anemia and long-term, all-cause mortality in patients with AMI recruited from the MONICA/KORA myocardial infarction registry and to incorporate severity of anemia into the analysis.

Presence of anemia was defined based on Hb concentration (g/dL) measured at hospital admission and patients were categorized according to WHO classification of anemia [6]. Mild anemia was defined as Hb concentration of 11 to < 12 g/dL in women and 11 to < 13 g/dL in men. Moderate to severe anemia was present when Hb concentration was below 11 g/dL. Since only thirteen patients had severe anemia (Hb < 8 g/dL), no further subdivisions were made.

In order to examine whether an impaired renal function was present, we used the estimated glomerular filtration rate (eGFR) and applied the Modification of Diet in Renal Disease (MDRD) study equation (eGFR (ml/min/1.73 m2) = 186.3 × (serum creatinine−1.154) × (age−0.203) × 0.742 (if female) × 1.212 (if black)) [14] to calculate it. Risk factors such as history of angina pectoris, prior myocardial infarction, hypertension, hyperlipidemia, diabetes mellitus, stroke as well as patients’ smoking habits were covered during the interview conducted by the study nurses and confirmed by chart review (except for history of stroke and smoking habits). Body mass index (BMI; kg/m2), systolic and diastolic blood pressure as well as heart rate and AMI classification (ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or bundle branch block) were derived from chart review only. Echocardiography, ventriculography and radionuclide ventriculography were used to determine whether patients had a reduced left ventricular ejection fraction (LVEF < 30%). Furthermore, medications administered at discharge were documented. The majority of patients received antiplatelet agents, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor-blockers (ARB), beta-blockers and statins at discharge and therefore, we included these medications as one covariate (4 evidence-based medications (EBM); yes/no). In-hospital procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) were determined by chart review. Since in-hospital complications rarely occurred, a single covariate was generated including the occurrence of cardiac arrest, pulmonary edema, bradycardia, re-infarction, ventricular tachycardia, ventricular fibrillation or cardiogenic shock.

Possible differences in survival were tested using Kaplan-Meyer plots as well as log-rank tests. Hazard ratios (HR) for all-cause mortality according to anemia status were calculated using Cox regression models. Three different models were calculated: 1) an unadjusted model, 2) a model adjusted for age and sex, and 3) a model adjusted for age, sex, previous MI, angina pectoris, hyperlipidemia, diabetes, stroke, eGFR, heart rate, AMI type, LVEF, discharge medications, PCI and in-hospital complications. Covariates made it into the latter model if the corresponding log-rank-test was statistically significant (p < 0.05) and if they proved to make a statistically significant contribution to predicting all-cause mortality in a model together with anemia status. We graphically tested whether the assumption of proportional hazards (parallel lines of log (−log (event)) versus log of event times) was valid for each covariate. Time-dependent
interaction terms were included if the assumption was rejected. The covariates age and sex were included into each model independent of statistical significance. Due to frequently missing data, LVEF was entered into the regression model as a dummy coded variable (LVEF < 30%; yes/no/missing). The variance inflation factor (VIF) was used to detect multicollinearity among covariates [15]. Furthermore, we calculated adjusted Cox regression models for increasing observation periods ranging from one to 6 years.

As a sensitivity analysis, we calculated a Cox regression model including all patients who were originally excluded from our study population due to missing information on any covariate (n = 176). We adjusted this model for sex and age. Patients without anemia served as the reference category for all analyses. P-values of < 0.05 were considered statistically significant. The analyses were performed using statistical software package SAS version 9.2 (SAS Institute Inc., Cary, NC).

**Results**

In total, 283 AMI patients (14.1%) were considered anemic based on admission Hb concentration. Of those patients, 183 (64.7%) were mildly anemic, whereas 100 (35.3%) had moderate to severe anemia. Male patients accounted for 75.6% of the total study population and the mean age was 60.9 ± 9.6 years. Further patient characteristics are summarized in Table 1.

Patients without anemia differed from the group with anemia concerning a majority of patient characteristics: they were significantly younger, had a higher BMI and were less likely to smoke (see Table 1). In terms of known comorbidities and other risk factors, the non-anemia group was overall healthier. They were less likely to have diabetes and to have suffered from prior myocardial infarction, angina pectoris and stroke. Additionally, they had a significantly higher eGFR on admission. Patients with anemia were less likely to receive antplatelet agents, ACEIs/ARBs and statins, but more often received diuretics and insulin at hospital discharge. Patients with anemia more often had a LVEF < 30% and information on LVEF was more frequently missing than in patients without anemia.

During a median follow-up time of 4.2 years (IQR 3.1–5.4), 241 (12.0%) patients with AMI died. Patients with anemia had a significantly higher long-term mortality (n = 85, 30.0%) compared to patients without anemia (n = 156, 9.0%). A higher percentage of patients died in the group with moderate to severe anemia (n = 37, 37.0%) than in the group with mild anemia (n = 48, 26.2%). Kaplan-Meier plots showing survival curves stratified by anemia status and the corresponding log-rank p-value are provided in Fig. 1. Patients who died during follow-up were significantly older, had a lower eGFR and were more likely to have an impaired LVEF compared to those without an event during follow-up (data not shown). Furthermore, they received four EBM at discharge significantly less often (data not shown).

Results of the Cox regression analyses are shown in Table 2.

In the unadjusted model, patients with mild anemia and patients with moderate to severe anemia had significantly increased mortality risks compared to the non-anemia group by factor of 3.35 and 5.22, respectively. With increasing adjustment, HRs decreased but still remained statistically significant. Interaction terms were each included in a regression model together with anemia status due to a rejected proportionality assumption for sex, age, BMI, smoking habits, history of angina pectoris, history of diabetes, AMI type, LVEF, eGFR and heart rate. None of the interaction terms made a statistically significant contribution to the models. Despite the adjustment, patients with moderate to severe anemia still had a 2 times higher mortality risk (HR 2.05, 95% CI 1.37–3.05) compared to the reference group. In patients with mild anemia, the risk of dying was increased by 74% in the final model (HR 1.74, 95% CI 1.23–2.45). Possible multicollinearity among covariates was rejected since the VIF did not exceed the threshold value of 2.5.

Cox regression models for increasing observation periods showed decreasing HRs in both groups with anemia (see Additional file 1: Figure S1). After 1 year, both anemia groups had a 2.4-times increased risk of dying. The risk decreased to HRs of 1.7 and 2.1 in patients with mild anemia and moderate to severe anemia 6 years after AMI, respectively. Estimates drifted apart starting at 3 years of observation period.

The sensitivity analysis showed increased HRs in patients with moderate to severe anemia (HR 4.19 vs. 3.94) and attenuated HRs in patients with mild anemia (HR 2.46 vs. 2.71) compared to the results from our actual study population (see Additional file 2: Table S1). The estimates remained statistically significant.

**Discussion**

In the present analysis, we demonstrated that anemia on admission both the mild and moderate to severe type was associated with higher long-term all-cause mortality in patients hospitalized for AMI. HRs attenuated after multivariate adjustment, but a considerable and statistically significant difference in mortality risk persisted. Similar risks for patients in both anemia groups were found 1 year after AMI before they decreased and drifted apart with increasing observation periods.

In patients with coronary artery disease, the prevalence of anemia on admission varied widely across previous studies and ranged from 11% [10] to up to 38% [11]. Compared to most previous studies, the prevalence of anemia in our population (14.1%) was low [1, 8, 10, 11, 16–21]. Those studies focused either only on patients with STEMI or
Table 1 Baseline characteristics and long-term mortality of patients with AMI by anemia status (n = 2011)

| Anemia\(^a\) (n = 283) | Non-anemia\(^d\) (n = 1728) | p Value |
|------------------------|-------------------------------|---------|
| Total                  | Mild anemia\(^b\) (n = 183)  | Moderate to severe anemia\(^c\) (n = 100) |

### Socio-demographic characteristics

|                                |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|
| Age (years)                    | 64.8 ± 8.5 | 64.5 ± 8.5 | 65.4 ± 8.4 | 60.1 ± 9.6 | < 0.0001 |
| Female                         | 70 (24.7) | 43 (23.5) | 27 (27.0) | 440 (25.5) | 0.7838   |
| Living alone, (n = 1939)       | 54 (20.7) | 35 (20.2) | 19 (21.6) | 291 (17.34) | 0.4057   |

### Risk factors and medical history

|                                |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|
| BMI (kg/m\(^2\), (n = 1934)    | 27.2 ± 4.8 | 27.4 ± 4.8 | 26.8 ± 4.9 | 28.0 ± 4.5 | 0.0272   |
| Smoking status, (n = 1886)     |       |       |       | < 0.0001 |
| Smoker                         | 55 (22.7) | 36 (22.5) | 19 (23.2) | 661 (40.2) |
| Ex-smoker                      | 102 (41.2) | 70 (43.8) | 32 (39.0) | 515 (31.3) |
| Never smoker                   | 85 (35.1) | 54 (33.8) | 31 (37.8) | 468 (28.5) |
| Prior myocardial infarction    | 41 (14.5) | 24 (13.2) | 17 (17.0) | 165 (9.6)  | 0.0228   |
| Angina pectoris                | 71 (25.1) | 51 (27.9) | 20 (20.0) | 282 (16.3) | 0.0004   |
| Hypertension                   | 230 (81.3) | 142 (77.6) | 88 (88.0) | 1367 (79.1) | 0.0830   |
| Hyperlipidemia                 | 164 (58.0) | 107 (58.5) | 57 (57.0) | 1118 (64.7) | 0.0884   |
| Diabetes                       | 123 (43.5) | 68 (37.2) | 55 (55.0) | 488 (28.2) | < 0.0001 |
| Stroke                         | 38 (13.4) | 21 (11.5) | 17 (17.0) | 85 (4.9)  | < 0.0001 |

### Laboratory markers

|                                |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|
| Hemoglobin (g/dL)              | 11.2 ± 1.6 | 12.1 ± 0.6 | 9.5 ± 1.3 | 14.8 ± 1.3 | < 0.0001 |
| eGFR (ml/min/1.73m\(^2\))      | 63.9 (43.4–85.5) | 65.9 (47.4–83.4) | 60.3 (35.9–88.4) | 78.3 (64.4–92.3) | < 0.0001 |
| eGFR < 60 ml/min/1.73m\(^2\)   | 122 (43.1) | 73 (39.9) | 49 (49.0) | 329 (19.0) | < 0.0001 |

### Clinical characteristics

|                                |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|
| Systolic blood pressure (mmHg) | 120 ± 17 | 120 ± 16 | 121 ± 19 | 118 ± 15 | 0.0746   |
| Diastolic blood pressure (mmHg)| 68 ± 10 | 68 ± 10 | 67 ± 11 | 69 ± 10 | 0.1236   |
| Heart rate (bpm)               | 73 ± 11 | 73 ± 11 | 73 ± 10 | 71 ± 10 | 0.0004   |
| AMI type                       |       |       |       | < 0.0001 |
| STEMI                          | 63 (22.3) | 46 (25.14) | 17 (17.0) | 616 (35.6) |
| NSTEMI                         | 194 (68.6) | 120 (65.6) | 74 (74.0) | 1019 (59.0) |
| Bundle branch block            | 26 (9.2) | 17 (9.3) | 9 (9.0) | 93 (5.4) |
| LVEF (n = 1188)                |       |       |       | 0.0021   |
| LVEF < 30%                     | 4 (2.9) | 3 (1.6) | 1 (1.0) | 38 (2.2) |
| LVEF ≥30%                      | 132 (46.6) | 87 (47.5) | 45 (45.0) | 1014 (58.7) |
| Missing                        | 147 (51.9) | 93 (50.8) | 54 (54.0) | 676 (39.1) |

### Medication at discharge

|                                |       |       |       |       |
|--------------------------------|-------|-------|-------|-------|
| Antiplatelet agents            | 263 (92.9) | 172 (94.0) | 91 (91.0) | 1686 (97.6) | < 0.0001 |
| ACEIs/ARBs                     | 225 (79.5) | 149 (81.4) | 76 (76.0) | 1493 (86.4) | 0.0045   |
| Beta-blocker                   | 271 (95.8) | 175 (95.6) | 96 (96.0) | 1728 (96.1) | 0.9595   |
| Statins                        | 239 (84.5) | 161 (88.0) | 78 (78.0) | 1636 (94.7) | < 0.0001 |
| 4 EBM                          | 178 (62.9) | 125 (68.3) | 53 (53.0) | 1358 (78.6) | < 0.0001 |
| Calcium channel blocker        | 49 (17.3) | 33 (18.0) | 16 (16.0) | 216 (12.5) | 0.0758   |
| Diuretics                      | 184(65.0) | 115 (62.8) | 69 (69.0) | 877 (50.8) | < 0.0001 |
| Insulin                        | 57 (20.1) | 30 (16.4) | 27 (27.0) | 147 (8.5)  | < 0.0001 |
| Other antidiabetic agents      | 51 (18.0) | 31 (16.9) | 20 (20.0) | 225 (13.0) | 0.0594   |
Table 1 Baseline characteristics and long-term mortality of patients with AMI by anemia status (n = 2011) (Continued)

| In-hospital treatment | Anemia* (n = 283) | Non-anemia† (n = 1728) | p Value |
|----------------------|-------------------|------------------------|---------|
|                      | Total             | Mild anemia b (n = 183) | Moderate to severe anemia c (n = 100) | Non-anemia† (n = 1728) | p Value |
| PCI                  | 139 (49.1)        | 102 (55.7)             | 37 (37.0) | 1335 (77.3) | < 0.0001 |
| CABG                 | 66 (23.3)         | 39 (21.3)              | 27 (27.0) | 235 (13.6) | < 0.0001 |
| Any in-hospital complication d | 51 (18.0) | 31 (16.9) | 20 (20.0) | 229 (13.3) | 0.0773 |
| Outcome              |                   |                        |          |             |         |
| All-cause mortality  | 85 (30.0)         | 48 (26.2)              | 37 (37.0) | 156 (9.0)  | < 0.0001 |

AMI acute myocardial infarction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin-receptor blocker, BMI body mass index, CABG coronary artery bypass graft, EBM evidence-based medications (antiplatelet agents, ACEIs/ARBs, beta-blockers, statins), eGFR estimated glomerular filtration rate, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention

Data are presented as n (%), mean ± standard deviation or median (interquartile range (25%-quartile – 75%-quartile))

* Anemia: Hemoglobin (Hb) concentration of < 12 g/dL in women, Hb concentration of < 13 g/dL in men

b Mild anemia: Hb concentration of 11 g/dL to < 12 g/dL in women, Hb concentration of 11 g/dL to < 13 g/dL in men

c Moderate to severe anemia: Hb concentration of < 11 g/dL in men and women

d Non-anemia: Hb concentration of ≥12 g/dL in women, Hb concentration of ≥13 g/dL in men

e Any in-hospital complication includes at least one of the following: cardiac arrest, pulmonary edema, bradycardia, re-infarction, ventricular tachycardia, ventricular fibrillation, cardiogenic shock

Fig. 1 Kaplan-Meier curve with log-rank test p-value of 6-year survival by anemia status. Hb, Hemoglobin
included all patients with acute coronary syndrome (ACS), which might explain the disparities. A higher prevalence of anemia was found in previous studies in patients with AMI [1, 5, 11]. This could derive from the fact that we excluded patients who survived for 28 days or less, which reduced the prevalence of anemia in our study population.

In line, studies with observation periods of at least 1 year found significant associations between admission anemia and long-term mortality [1, 16, 18, 22–24]. Anemia predicted 1-year survival in ACS patients [18] and 2-year survival or AMI in men with ACS [22]. In patients with STEMI, anemia was significantly associated with an increased cardiovascular mortality risk after 21 months [23], major cardiovascular events (MACE) after 5-years [16] and all-cause mortality after 6-years of follow-up [24]. Ducrocq et al. examined 3541 patients with AMI and found a 5-year mortality risk increased by 40% in patients with anemia (HR 1.4, 95% CI 1.2–1.6) [1]. In comparison, the mortality risk found in patients with anemia from our study population was increased by 80%. Among other known risk factors, Ducrocq et al. adjusted their regression analysis for in-hospital bleeding and transfusion [1]. Studies have shown that patients with anemia are more susceptible to experience major bleeding after cardiac events and revascularization [3, 25], which might also affect their long-term mortality risk [1, 25]. Apart from advising to use certain antiplatelet agents with care to avoid bleeding in patients with anemia after AMI [26], current clinical practice guidelines do not provide specific recommendations for the management of anemia in those patients [27]. In terms of AMI treatment using PCI, a study showed that radial instead of femoral access might reduce the risk of bleeding in patients with AMI [28]. Due to the lower risk of bleeding, the radial access might also be preferable when performing PCI in patients with anemia. Furthermore, assuming that patients with anemia are more likely to receive blood transfusion than patients without anemia, an increased risk of “transfusion-associated mortality” [29] might exist. Clinical practice guidelines regarding blood transfusion recommend a Hb threshold of 7–8 g/dL in hospitalized patients [30]. However, transfusion should be taken into consideration in patients with acute coronary syndrome and a Hb concentration of 8–10 g/dL [30]. Data on both in-hospital bleeding and transfusion were not collected in the framework of the registry and, therefore, the possibility exists that we overestimated the mortality risk in patients with anemia. Given the prognostic importance, future studies should include data on bleeding as well as blood transfusions and a Hb threshold for blood transfusion in patients with AMI should be determined.

Furthermore, we subdivided patients with anemia and found increased mortality risks already in patients with mildly reduced Hb concentration. This could have been concealed in previous studies only distinguishing between patients with anemia and those without. Younge et al. examined patients with ACS (defined as STEMI or NSTEMI) who were followed up for over 20 years and found significantly increased mortality risks in those with moderate (HR 1.13) and severe anemia (HR 1.39), but not in those with mild anemia [11]. In their study, patients with anemia were subdivided by tertiles, which deviated from the WHO classification. The cut-off points, especially those for men with mild anemia (12.2–13.0 g/dL vs. 11–13 g/dL in our study) might be responsible for different survival estimates found in their study [11]. Nonetheless, both our and their results stress the need to account for severity of anemia in future studies. Furthermore, our analysis of increasing observation periods showed that severity of anemia might not be important in the first 2 years after AMI but might become more relevant in subsequent years.

Inconsistent with our results, a study in patients with STEMI treated with primary PCI did not confirm an association after 3 years of follow-up [19]. Besides it
being a single center study, differences in study population could explain the inconsistency with our results. Furthermore, the authors argue that not anemia itself might negatively impact long-term survival, but rather other comorbidities could explain the worse prognosis [19]. In our study and most previous studies [1, 10, 11, 23], patients with anemia were more likely to be older, were affected by more comorbidities, had an impaired eGFR as well as a lower LVEF. Even though important comorbidities were included in our analysis, data on other measures of overall health status were not available. Additionally, patients with anemia differed from those without anemia regarding in-hospital treatment. They were less often treated with PCI, but more frequently with CABG, which might be an indicator of more advanced coronary artery disease. In line, previous studies demonstrated that anemic patients were less often treated with PCI [18, 21] and experienced worse outcomes after PCI, e.g. increased risks for stent thrombosis, long-term mortality, MACE and bleeding [3, 4, 23, 31]. Furthermore, patients with anemia were less likely to receive 4 EBM at hospital discharge, which is considered the standard of care in patients after AMI and has been shown to significantly reduce long-term mortality [32]. Out of the 4 EBM, both patients with mild and moderate to severe anemia were less likely to receive antithrombotic agents, ACEIs/ARBs and statins compared to patients without anemia. In line, a study in STEMI patients showed that those with anemia were less frequently treated according to guidelines in terms of pharmacological treatment compared to those without anemia [20]. However, less often receiving 4 EBM could also be a consequence of other pre-existing diseases apart from anemia such as impaired renal function [33].

Multiple factors might influence long-term mortality after AMI in patients with anemia. When anemia is present, the amount of oxygen delivered to the heart during AMI is further decreased, myocardial tissue oxygenation is likely to be insufficient and cardiac output is increased [31, 34]. Possibly entailing an impaired recovery after AMI [16], anemia might affect mortality, but cannot solely explain the significantly worse long-term outcomes in patients with AMI. Even though both mild and moderate to severe anemia did predict an increased risk for long-term mortality independent of a number of confounders in our study population, treatment strategies that aim at increasing Hb concentration in patients with AMI and anemia might not significantly benefit long-term survival. In line, a recent randomized controlled trial demonstrated that administering erythropoietin after PCI, a hypoxia-induced hormone that also regulates Hb concentration, did not have beneficial effects on long-term outcomes [35].

Our study is characterized by several strengths. Data was collected in the framework of a population-based registry and patients with AMI were consecutively enrolled. Important risk factors such as comorbidities, in-hospital treatment and complications, relevant laboratory values as well as medications received at hospital discharge were included in our analysis. A longer follow-up than most previous studies and the analysis of increasing observation periods add valuable information to existing research.

This study has limitations. First, even though several risk factors potentially affecting survival after AMI were included, data on cancer, gastro-intestinal or other chronic diseases was not collected. Second, we had no information on the etiology of anemia and how it was treated (e.g. using iron therapy). Knowing the cause of abnormal Hb concentrations would considerably contribute to the understanding of the association between anemia and long-term mortality. Third, any other events occurring after hospital discharge apart from all-cause mortality and possibly affecting survival could not be monitored. Fourth, a reduced LVEF is a marker for heart failure and data on LVEF was not available in all patients in our study population. Since we included those patients with missing values for left-ventricular ejection fraction we cannot rule out potential bias. Finally, due to the methodological limitations of an observational study, a causal relationship between admission anemia and long-term mortality cannot be established with absolute certainty and the possibility of reverse causation exists.

Conclusion

Both mild and moderate to severe anemia were associated with significantly increased long-term, all-cause mortality risks in our study population and low admission Hb concentration needs to be considered as a risk factor in patients with AMI. However, even though our results confirm what most other studies have found in patients with AMI before, it remains unclear if anemia alone can predict long-term mortality after AMI or if it is merely a proxy for worse overall health. Future studies need to take severity of anemia, bleeding events and blood transfusion as well as overall health status into account.

Additional files

Additional file 1: Figure S1. Hazard ratios for long-term mortality in patients with AMI and anemia covering increasing observation periods. Reference: Non-anemia: Hemoglobin (Hb) concentration of >21 g/dL in women, >23 g/dL in men; Mild anemia: Hb concentration of 11 g/dL to <12 g/dL in women, >11 g/dL to <13 g/dL in men; Moderate to severe anemia: Hb concentration of <11 g/dL in women and men. 95% Confidence intervals (CI) are represented by vertical lines above and below the HR estimates; 95% CI for mild anemia: dashed line; 95% CI for moderate to severe anemia: continuous line. AMI, Acute myocardial infarction; CI, Confidence interval; Hb, Hemoglobin; HR, Hazard ratio. (PDF 49 kb)

Additional file 2: Table S1. Results of the sensitivity analysis (n = 2187). (DOCX 16 kb)


Abbreviations
ACEI: Angiotensin-converting enzyme inhibitor; ACS: Acute coronary disease; AMI: Acute myocardial infarction; ARB: Angiotensin-receptor blockers; BMI: Body mass index; CABG: Coronary artery bypass graft; EBM: Evidence-based medication; eGFR: Estimated glomerular filtration rate; Hb: Hemoglobin; HR: Hazard ratio; IQR: Interquartile range; KORA: Cooperative Health Research in the Region of Augsburg; LVEF: Left ventricular ejection fraction; MACE: Major cardiovascular event; MDIR: Modification of Diet in Renal Disease; MI: Myocardial infarction; MONICA: Monitoring Trends and Determinants in Cardiovascular disease; NSTEMI: Non-ST-segment elevation myocardial infarction; PCI: Percutaneous coronary intervention; SD: Standard deviation; SPC: Serum potassium concentration; STEMI: ST-elevation myocardial infarction; VIF: Variance inflation factor; WHO: World Health Organization

Acknowledgements
We thank all members of the Helmholtz Zentrum München, Institute of Epidemiology and the field staff in Augsburg who were involved in the planning and conduct of the study. We wish to thank the local health departments, the office-based physicians and the clinicians of the hospitals within the study area for their support. Finally, we express our appreciation to all study participants.

Funding
The KORA research platform and the MONICA Augsburg studies were initiated and financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education, Science, Research and Technology and by the State of Bavaria. Since the year 2000, the collection of MI data has been co-financed by the German Federal Ministry of Health to provide population-based MI morbidity data for the official German Health Report (see www.gbe-bund.de). Steering partners of the MONICA/KORA Infarction Registry, Augsburg, include the KORA research platform, Helmholtz Zentrum München and the Department of Internal Medicine I, Cardiology, Central Hospital of Augsburg.

Availability of data and materials
The data that support the findings of this study are available from Helmholtz Zentrum München but restrictions apply to the availability of data, which were used under license for the current study, and are not publicly available. Due to restrictions from Helmholtz Zentrum München, data are available upon request for any researcher based on a standard agreement on data provision within the KORA Research Platform.

Authors’ contributions
MGC, IK and CM conceived the study. MGC performed the statistical analyses and drafted the manuscript. CM, UA, MH, BK, CT, and AP contributed to the interpretation of data. CM, MH, BK and CT contributed to data acquisition. IK, UA, MH, CT, BK, AP and CM read, critically revised and approved the final manuscript.

Ethics approval and consent to participate
Data collection and follow-up questionnaires have been approved by the ethics committee of the Bavarian Medical Association (Bayerische Landesärztekammer) and have been performed in accordance with the Declaration of Helsinki. All study participants gave written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1MONICA/KORA Myocardial Infarction Registry, Central Hospital of Augsburg, Augsburg, Germany. 2Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany. 3Chair of Epidemiology, Ludwig-Maximilians-Universität München, UNIKlinikum Augsburg. 4Department of Internal Medicine I – Cardiology, Central Hospital of Augsburg, Augsburg, Germany. 5Department of Internal Medicine/ Cardiology, Hospital of Nördlingen, Nördlingen, Germany.

Received: 30 November 2017 Accepted: 26 February 2018
Published online: 09 March 2018

References

1. Ducrocq G, Puymirat E, Steg PG, Henry P, Mantelet M, Karam C, Schiele F, Simon T, Danchin N. Blood transfusion, bleeding, anemia, and survival in patients with acute myocardial infarction: FAST-MI registry. Am Heart J. 2015;170(4):726–34. e722
2. Leibundgut G, Gick M, Morel O, Ferenc M, Werner KD, Comberg T, Kienzle RP, Buettner HJ, Neumann FJ. Discordant cardiac biomarker levels independently predict outcome in ST-segment elevation myocardial infarction. Clin Res Cardiol. 2016;105(5):432–40.
3. Wang X, Qiu M, Qi J, Li J, Wang H, Li Y, Han Y. Impact of anemia on long-term ischemic events and bleeding events in patients undergoing percutaneous coronary intervention: a system review and meta-analysis. J Thorac Dis. 2015;7(11):2041–52.
4. Nikolov E, Mehran R, Aymong ED, Mintz GS, Lansky AJ, Lasic Z, Negota M, Fahy M, Pocock SJ, Na Y, et al. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. Am J Cardiol. 2004;94(8):1023–8.
5. Aronson D, Suleiman M, Agmon Y, Suleiman A, Blich M, Kapeliovich M, Beyar R, Markievicz W, Hammerman H. Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction. Eur Heart J. 2007;28(11):1289–96.
6. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System [http://www.who.int/vmnis/indicators/haemoglobin.pdf].
7. Martinsson A, Andersson C, Andell P, Koul S, Engstrom G, Smith JG. Anaemia in the general population: prevalence, clinical correlates and prognostic impact. Eur J Epidemiol. 2014;29(7):489–98.
8. Ang DS, Kao MP, Noman A, Lang CC, Struthers AD. The prognostic significance of early and late anaemia in acute coronary syndrome. QJM. 2012;105(5):445–54.
9. Jonsson A, Hallberg AC, Edner M, Lund LH, Dahlstrom U. A comprehensive assessment of the association between anaemia, clinical covariates and outcomes in a population-wide heart failure registry. Int J Cardiol. 2016;211:124–31.
10. Bolinski S, Sobkowicz B, Zaninek J, Chlebnicka I, Bolinski J, Milewski R, Tycinska A, Musial W. The significance of anaemia in patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Kardiol Pol. 2011;69(1):33–9.
11. Younge JO, Nauta ST, Akkerhus CM, Deckers JW, van Domburg RT. Effect of anaemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes. Am J Cardiol. 2012;109(4):506–10.
12. Meisinger C, Hormann A, Heier M, Kuch B, Lowel H. Admission blood glucose and adverse outcomes in non-diabetic patients with myocardial infarction in the reperfusion era. Int J Cardiol. 2006;113(2):229–35.
13. Kuch B, Heier M, von Scheidt W, Kling B, Hoermann A, Meisinger C. 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/Agora AMI registry (1985–2004). J Intern Med. 2008;264(3):254–64.
14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1990;113(2):229–35.
15. When can you safely ignore multicollinearity? [http://statisticalhorizons.com/multicollinearity].
16. Uchida Y, Ichimiya S, Ishi H, Kanahiroo M, Watanabe J, Hayano S, Suzuki S, Takeshita K, Sakai S, Amano T, et al. Impact of admission anemia on coronary microcirculation and clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int Heart J. 2015;56(4):381–8.
17. Barbarova I, Klempfner R, Rapoport A, Wasserstrum Y, Goren I, Katz A, Segal G. Avoidance of blood transfusion to patients suffering from myocardial injury and severe anemia is associated with increased long-term mortality: a retrospective cohort analysis. Medicine (Baltimore). 2015;94(38):e1635.

18. Kanadian V, Mehran R, Lincoff AM, Felt F, Manoukian SV, Harion M, Cox DA, Dansg GD, Stone GW. Effect of anemia on frequency of short- and long-term clinical events in acute coronary syndromes (from the acute catheterization and urgent intervention triage strategy trial). Am J Cardiol. 2014;114(12):1823–9.

19. Rathod KS, Jones DA, Rathod VS, Bromage D, Gutmann O, Gallagher SM, Riley RF, Newby LK, Don CW, Alexander KP, Peterson ED, Peng SA, Gandhi SK, Kutcher MA, Amsterdam EA, Harrington DM. Guidelines-based treatment of anaemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR. Eur Heart J Acute Cardiovasc Care. 2013;2(1):35–43.

20. Riley RF, Newby DK, Don OH, Alexander KP, Peterson ED, Peng SA, Gandhi SK, Kutcher MA, Amsterdam EA, Harrington DM. Guidelines-based treatment of anaemic STEMI patients: practice patterns and effects on in-hospital mortality: a retrospective analysis from the NCDR. Eur Heart J Acute Cardiovasc Care. 2013;2(1):35–43.

21. Sulaiman K, Prashanth P, Al-Zakwani I, Al-Mahmeed W, Al-Motarreb A, Al. Anticoagulation strategy on major bleeding and mortality: a historical cohort analysis in the veteran population. Cardiovasc Revasc Med. 2018;19(1 Pt B):95–103.

22. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caso V, Gentilcore D, Gómez-Sendra L, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation myocardial infarction: in-hospital and long-term clinical outcomes. Coron Artery Dis. 2011;22(6):375–9.

23. Tomaszuk-Kazberuk A, Bolinska S, Mlodawska E, Lopatowska P, Sobkowicz B, Tomaszuk-Kazberuk A, Bolinska S, Mlodawska E, Lopatowska P, Sobkowicz B, Musial W. Does admission anaemia still predict mortality six years after myocardial infarction? Kardiol Pol. 2014;72(6):488–93.

24. Ayhan E, Aydilek F, Uyarel H, Ergelen M, Cicek G, Gul M, Osmanov D, Yildirim E, Bozbay M, Ugur M, et al. Patients with anaemia on admission who have undergone primary angioplasty for ST elevation myocardial infarction: in-hospital and long-term clinical outcomes. Coron Artery Dis. 2011;22(6):375–9.

25. Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Mockel M, Ochala A, Mehran R, et al. Impact of anaemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). Am J Cardiol. 2010;105(10):1385–94.

26. Ibanez B, James S, Agevall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Cafiero ALP, Crea F, Goudevenos JA, Halvorsen S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Rev Esp Cardiol (Engl Ed). 2017;70(12):1082.

27. Kwok CS, Tong D, Pradhan A, Andreou AY, Nolan J, Bertrand OF, Curzen N, Delgado V, Desai NS, et al. Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals. J Am Coll Cardiol. 2014;64(8):811–9.

28. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316(19):2025–35.

29. Pilgrim T, Vetterli F, Kalesan B, Stefanini GG, Raber L, Stortecky S, Glöckler S, Binder RK, Wenaweser P, Moschovitis A, et al. The impact of anemia on long-term clinical outcome in patients undergoing revascularization with the unrestricted use of drug-eluting stents. Circ Cardiovasc Interv. 2012;5(2):202–10.

30. Amann U, Kirchberger I, Heier M, Goudevenos JA, Halvorsen S, Meisinger C. Long-term survival in patients with different combinations of evidence-based medications after incident acute myocardial infarction: results from the MONICA/KORA myocardial infarction registry. Clin Res Cardiol. 2014;103(8):655–64.

31. Khedir M, Szummer K, Carrero JJ, Jemberg T, Evans M, Jacobson SH, Spaak J. Systematic underutilization of secondary preventive drugs in patients with acute coronary syndrome and reduced renal function. Eur J Prev Cardiol. 2017;24(7):724–754.